Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s)
US8202969B2 · kind B2 · utility
0Cited by
10References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 3, 2010 |
| Grant date | Jun 19, 2012 |
| Priority date | — |
| Expiry date | Dec 3, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.